TORONTO, Dec. 9, 2014 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved its application for the generic version of PrTarceva®. Teva Canada will be the sole generic supplier of this treatment in Canada.
PrTeva-Erlotinib is indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen, as well as monotherapy for maintenance treatment in patients with stable disease after four cycles of standard first-line chemotherapy. PrTeva-Erlotinib is also indicated as monotherapy for the first-line treatment of patients with locally advanced (stage III b, not amenable to curative therapy) or metastatic (stage IV) NSCLC with EGFR activating mutations.
PrTarceva® had annual sales of approximately $15 million in Canada, based on IMS Brogan sales data as of September 2014. PrTeva-Erlotinib is available immediately in pharmacies across Canada.
"With today's announcement, Teva Canada's industry-leading oncology portfolio containing 23 drug products is helping to mitigate the rising costs of cancer treatment in Canada," said Doug Sommerville, Senior Vice President and General Manager, Teva Canada Limited. "Adding PrTeva-Erlotinib to our ever-expanding portfolio of oncology products demonstrates our ongoing commitment to playing a critical role in the sustainability of the healthcare system."
Lung cancer is the most commonly diagnosed cancer in Canada and the Canadian Cancer Society estimates that in 2014 there will be 26,100 new cases diagnosed, representing 14 per cent of all new cancer cases this year. i The most common malignant tumour found in the lung is non-small cell lung cancer (NSCLC), accounting for 85 to 90 percent of all lung cancers.ii
About Teva Canada Limited
Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare solutions for almost 50 years, with nearly 200,000iii prescriptions filled with our products every day. Originally Novopharm Limited, Teva Canada specializes in the development, production and marketing of high-quality generic prescription pharmaceuticals and through our branded division, Teva Canada Innovation, focuses on a diverse line of innovative products in a variety of therapeutic areas. Teva Canada employs more than 1,300 individuals, markets more than 400iv products in Canada and is a subsidiary of Teva Pharmaceutical Industries Ltd., the world's largest generic drug maker. For more information, visit: www.tevacanada.com or www.tevamakesmedicines.ca.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs, as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries. Teva's Specialty Medicines businesses focus on CNS, respiratory, oncology, pain, and women's health therapeutic areas, as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $20.3 billion in net revenues in 2013.
i Canadian Cancer Society. Lung cancer statistics. https://www.cancer.ca/en/cancer-information/cancer-type/lung/statistics/?region=on. Accessed November 19, 2014.
ii Canadian Cancer Society. Malignant tumours of the lung. https://www.cancer.ca/en/cancer-information/cancer-type/lung/lung-cancer/non-small-cell-lung-cancer/?region=on. Accessed November 19, 2014.
iii IMS Compuscript TRx MAT September 2014
iv IMS CD&H MAT September 2014
SOURCE: Teva Canada Limited
For further information: Teva Pharmaceutical Industries Ltd., Denise Bradley, Vice-President, Head of Global Corporate Reputation, P. 215.591.8974, firstname.lastname@example.org